Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Start-up Arcus raises $120 million

by Michael McCoy
September 5, 2016 | A version of this story appeared in Volume 94, Issue 35

The chemist founders of Flexus Biosciences—which Bristol-Myers Squibb acquired last year for up to $1.25 billion—have started a new company called Arcus Biosciences. Coming out of so-called stealth mode, Arcus disclosed that it has raised $120 million in venture capital funding. The company’s first three compounds are small molecules intended to disrupt enzymatic conversion of adenosine triphosphate (ATP), released by dying cells, into adenosine. Whereas ATP is a signal to the immune system to respond to cancer, adenosine tells the immune system to stand down. CEO Terry Rosen expects two of the compounds to reach clinical trials in 2017.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.